Send to

Choose Destination
Allergy Asthma Clin Immunol. 2011 May 24;7(1):9. doi: 10.1186/1710-1492-7-9.

Long-term benefits of omalizumab in a patient with severe non-allergic asthma.

Author information

Department of Respiratory Diseases, Santa Maria Nuova Hospital, Reggio, Emilia, Italy.



Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.


We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.


Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center